The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

Inclusion Criteria: * Criteria to enter the study include males and females between the ages of 18-90 (females must be post menopausal) and a DSM-IV diagnosis of Major Depressive Disorder, Major Depressive Disorder with psychotic features, Bipolar Disorder, depressed type, or Schizoaffective Disorder, depressed type (19). Exclusion Criteria: * DSM-IV diagnoses of dementia and its subtypes * Substance use disorder (active use within the last 6 months) * Organic mental disorders; seizure disorder * Unstable physical disorder or physical disorder judged to significantly affect the central nervous system function * A heart rate of \<60 * A systolic blood pressure \< 90 * Heart block * Pre-existing sick-sinus * Chronic treatment with beta blockers * Any cardiac arrythmia * Hypotension * Coronary artery disease * Liver and renal function impairment * Urge incontinence, colitis Crohn's disease, GI motility disorders, asthma and COPD * Treatment with anti-cholinergic and cholinomimetic medications; and * Female patients who are pregnant. * Additionally, women subjects must be postmenopausal, surgically sterile, or using prescription oral contraceptives (e.g. estrogen-progestin combinations) , contraceptive implants (e.g. NorplantTM, DepoProveraTM ), or transdermally delivered contraceptives (Ortho EvraTM) before entry and throughout the study; and have a negative serum b-HCG pregnancy test at screening. Note: Abstinence and the use of double barrier contraceptive methods are not acceptable in this study.